AFP and hepatocellular carcinoma: The inclusion of telomerase inhibitors in a chemotherapy protocol for patients with hepatocellular carcinoma may have a negative effect on cell proliferation and immortalization by inhibiting telomere repair, by inhibiting the extra-telomeric cell surviving effect of telomerase, and by targeting AFP production, which is a growth factor by itself; however, more in vivo animal and clinical studies should be performed.